Clinical trial NCT05830539: IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients
Official title: A Phase Ib/II, Open-label, Multicenter Clinical Study to Evaluate the Antitumor Activities, Safety, and Tolerability of IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Locally Advanced or Metastatic Solid Tumors
Lead sponsor: InxMed (Shanghai) Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2023-04-26
Enrollment: 68
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a multicenter, open-label, Phase Ib/II clinical trial to evaluate the safety, tolerability, and antitumor efficacy of IN10018 in combination with pegylated liposomal doxorubicin (PLD) or IN10018 in combination with PLD and anti-PD-1 in subjects with locally advanced or metastatic solid tumors who have failed or not tolerated to at least first-line system therapy.

Detailed description: This study is a phase Ib/II, multicenter, open-label clinical study. This study consists of 2 parts: 1) Efficacy exploration part: including phase-Ib study (dose confirmation part) and phase II study, the purpose of phase Ib-dose confirmation part is to determine the Phase II recommended dose (RP2D) of IN10018 in combination with Pegylated liposomal doxorubicin (PLD) and programmed death-1 (PD-1) monoclonal antibody. The Phase II study will explore the antitumor efficacy and safety of IN10018 in combination with PLD or IN10018 in combination with PLD and anti-PD-1 monoclonal antibody in subjects with locally advanced or metastatic solid tumors who have failed or are intolerant to at least first-line system therapy; 2) Efficacy confirmation part: The antitumor efficacy and safety of combination therapy in the corresponding solid tumors will be further confirmed.

Eligibility criteria: Inclusion Criteria

1. Male or female, and aged 18 - 75 years at the time of signing the informed consent.
2. Has ability to understand and willingness to sign informed consent(s).
3. Histologically confirmed locally advanced or metastatic solid tumors:

   1. Cohort 1: Histologically-confirmed Locally advanced or metastatic triple-negative breast cancer.
   2. Cohort 2: Histologically or cytologically confirmed recurrent or metastatic head and neck squamous cell carcinoma.
   3. Cohort 3 and 4: Histologically confirmed epithelia ovarian cancer, fallopian tube cancer or primary peritoneum cancer with the subtype limited to high-grade serous carcinoma (HGSC) only.
   4. Cohort 5: Histologically confirmed extensive-stage small cell lung cancer (according to the Veteran's Administration Lung Cancer Study Group (VALG) classification system).
   5. Cohort 6: other Histologically confirmed locally advanced or metastatic solid tumors except cohort 1-5.
4. Have received at least 1 line of standard therapy for locally advanced or metastatic solid tumors and have failed or are not tolerable.
5. At least one measurable lesion can be accurately measured per RECIST 1.1 as assessed by investigator.
6. ECOG performance status of 0 or 1.
7. Life expectancy of at least 3 months as assessed by investigator.
8. Adequate bone marrow, liver, renal, and coagulation function within 7 days prior to first dose of study treatment.
9. Must have recovered from all AEs due to previous therapies to ≤ Grade 1 (CTCAE 5.0) or stable status as assessed by investigator.

Exclusion criteria

1. Has had major surgery or significant traumatic injury within 28 days prior to first dose of study treatment, or diagnostic biopsies within 14 days prior to first dose of study treatment.
2. Has received prior systemic anticancer therapy such as chemotherapy, biological therapy, endocrine therapy, immunotherapy, etc. within 4 weeks before the first dose.
3. History of autoimmune disease requiring systemic therapy within the past 2 years, including but not limited to autoimmune thyroid disease, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease.
4. Has interstitial pneumonia currently.
5. Has received prior treatment of any FAK inhibitor.
6. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
7. Has a prior history of malignancy other than the study disease.
8. Clinically symptomatic pleural effusion, pericardial effusion, or ascites, or those who have received or necessary for drainages within 3 months prior to the first dose of study treatment.
9. Has malabsorption syndrome or inability to take oral medication.
10. Has clinical or radiologic evidence of bowel obstruction, or prior recurrent bowel obstruction with the cause not eliminated within 3 months prior to the first dose of study treatment.
11. Has any active infection requiring systemic therapy within 14 days prior to the first dose of study treatment.
12. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
13. Known allergy or hypersensitivity to IN10018, PLD, or Toripalimab or their ingredients.
14. Pregnant or lactating women.
15. Has received prior cumulative doxorubicin or equivalent anthracyclines doses of 360 mg/m2 or more.
16. Has received systemic treatment of CYP3A4, CYP2D6 or P-gp strong inhibitors/inducers within 14 days prior to the first dose of study treatment, or anticipation of the systemic treatment of these drugs during Treatment Phase.

Primary outcomes:
measure: Recommended phase II dose (RP2D) of IN10018 in combination with PLD and anti-PD-1 monoclonal antibody.
timeFrame: Up to 6 Months
measure: Objective response rate (ORR) per RECIST v1.1 in IN10018 combined with PLD group or in IN10018 combined with PLD and anti-PD-1 monoclonal antibody group.
timeFrame: Up to 24 Months
Secondary outcomes:
measure: Number of patients with adverse event; Number of patients with laboratory abnormalities, abnormal vital signs and abnormal 12-lead ECG.
timeFrame: Up to 24 Months
measure: Duration of objective response (DOR) per RECIST v1.1 in IN10018 combined with PLD group or in IN10018 combined with PLD and anti-PD-1 monoclonal antibody group.
timeFrame: Up to 24 Months
measure: Disease Control Rate (DCR) per RECIST v1.1 in IN10018 combined with PLD group or in IN10018 combined with PLD and anti-PD-1 monoclonal antibody group.
timeFrame: Up to 24 Months
measure: Progression-free survival (PFS) per RECIST v1.1 in IN10018 combined with PLD group or in IN10018 combined with PLD and anti-PD-1 monoclonal antibody group.
timeFrame: Up to 24 Months
measure: Overall survival (OS) in IN10018 combined with PLD group or in IN10018 combined with PLD and anti-PD-1 monoclonal antibody group.
timeFrame: Up to 36 Months
Other outcomes:
Locations:
city: Anyang
country: China
facility: Anyang Tumor Hospital
state: Henan
city: Zhengzhou
country: China
facility: Henan Cancer Hospital
state: Henan
city: Zhengzhou
country: China
facility: Henan Provincial People's Hospital
state: Henan
city: Wuhan
country: China
facility: Hubei Cancer Hospital
state: Hubei
city: Changsha
country: China
facility: Hunan Cancer Hospital
state: Hunan
city: Nanchang
country: China
facility: The Third Hospital of Nanchang
state: Jiangxi
city: Shanghai
country: China
facility: Obstetrics & Gynecology Hospital of Fudan University
state: Shanghai
Study officials:
affiliation: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
name: Lingying WU
role: PRINCIPAL_INVESTIGATOR
affiliation: Fudan University
name: Xichun Hu
role: PRINCIPAL_INVESTIGATOR
affiliation: Fudan University
name: Dongmei Ji
role: PRINCIPAL_INVESTIGATOR
References: